National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. by Brizmohun Appayya, Mrishta et al.
National implementation of multi-parametric
magnetic resonance imaging for prostate cancer
detection – recommendations from a UK
consensus meeting
Mrishta Brizmohun Appayya1, Jim Adshead2, Hashim U. Ahmed3,4, Clare Allen5,
Alan Bainbridge6, Tristan Barrett7, Francesco Giganti3,5, John Graham8, Phil Haslam9,
Edward W. Johnston1,5, Christof Kastner10, Alexander P.S. Kirkham5, Alexandra Lipton11,
Alan McNeill12, Larissa Moniz13, Caroline M. Moore4,14, Ghulam Nabi15,
Anwar R. Padhani16, Chris Parker17, Amit Patel18, Jacqueline Pursey19,
Jonathan Richenberg20, John Staffurth21, Jan van der Meulen22, Darren Walls23 and
Shonit Punwani1,5
1Centre for Medical Imaging, 3Division of Surgery and Interventional Science, Faculty of Medical Sciences,
5Department of Radiology, 6Department of Medical Physics, 14Department of Urology, 23Division of Nuclear Medicine,
University College London Hospitals NHS Foundation Trust, University College London, 4Division of Surgery, Department
of Surgery and Cancer, Imperial College London and Imperial Urology, Imperial College Healthcare NHS Trust, 11The
Society and College of Radiographers, 13Prostate Cancer UK, 22London School of Hygiene and Tropical Medicine,
London, 2Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, 18Department of Radiology,
Lister Hospital, Stevenage, Hertfordshire , 7Department of Radiology, Addenbrooke’s Hospital and University of
Cambridge, 10Department of Urology, Addenbrooke’s Hospital and University of Cambridge, Cambridge, 8School of
Health and Related Research, University of Shefﬁeld, Shefﬁeld, 9Department of Radiology, Freeman Hospital, Newcastle
upon Tyne, 12Department of Urology, NHS Lothian, Western General Hospital, Edinburgh, 15Division of Cancer
Research, Ninewells Hospital, Dundee, 16Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood,
Middlesex, 17Department of Academic Urology, Royal Marsden Hospital, Sutton, Surrey, 19Department of Radiology,
Greater Glasgow and Clyde NHS Trust, Glasgow, 20Department of Radiology, Royal Sussex County Hospital Brighton
and Brighton and Sussex Medical School, Brighton, Sussex, and 21Division of Cancer and Genetics, School of
Medicine, Cardiff University, Cardiff, UK
Objectives
To identify areas of agreement and disagreement in the
implementation of multi-parametric magnetic resonance
imaging (mpMRI) of the prostate in the diagnostic
pathway.
Materials and Methods
Fifteen UK experts in prostate mpMRI and/or prostate
cancer management across the UK (involving nine NHS
centres to provide for geographical spread) participated in a
consensus meeting following the Research and Development
Corporation and University of California-Los Angeles
(UCLA-RAND) Appropriateness Method, and were
moderated by an independent chair. The experts considered
354 items pertaining to who can request an mpMRI,
prostate mpMRI protocol, reporting guidelines, training,
quality assurance (QA) and patient management based on
mpMRI levels of suspicion for cancer. Each item was
rated for agreement on a 9-point scale. A panel median
score of ≥7 constituted ‘agreement’ for an item; for an
item to reach ‘consensus’, a panel majority scoring was
required.
Results
Consensus was reached on 59% of items (208/354); these
were used to provide recommendations for the
implementation of prostate mpMRI in the UK. Key ﬁndings
include prostate mpMRI requests should be made in
consultation with the urological team; mpMRI scanners
should undergo QA checks to guarantee consistently high
diagnostic quality scans; scans should only be reported by
trained and experienced radiologists to ensure that men with
unsuspicious prostate mpMRI might consider avoiding an
immediate biopsy.
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Guidelines
Conclusions
Our consensus statements demonstrate a set of criteria that
are required for the practical dissemination of consistently
high-quality prostate mpMRI as a diagnostic test before
biopsy in men at risk.
Keywords
consensus methods, multi-parametric MRI, prostate cancer,
recommendations
Introduction
The prostate diagnostic pathway is currently based on
carrying out a TRUS-guided biopsy in men with an elevated
serum PSA. TRUS-guided biopsy involves taking 10–12
needle core biopsies from the prostate without prior
knowledge as to whether the man has cancer, and if he does,
where the cancer resides. This leads to over-diagnosis of
clinically insigniﬁcant cancers and missing cancers that are
clinically signiﬁcant, as well as the harms of deploying
needles through the rectum.
Multi-parametric MRI (mpMRI) of the prostate could
transform the prostate cancer clinical pathway [1–7]. A
recently published prospective multi-centre study (PROstate
MRI Imaging Study [PROMIS]) comparing the diagnostic
accuracy of mpMRI and TRUS biopsy demonstrated that
mpMRI outperforms TRUS biopsy as a diagnostic tool for the
detection of clinically signiﬁcant cancer. Further, PROMIS
showed that a quarter of men at risk could avoid immediate
biopsy as a result of unsuspicious mpMRI [8].
However, not all UK institutions have the ability to deliver
the beneﬁts of mpMRI to the extent reported within the
PROMIS [8]. At present, from a Freedom of Information
dataset acquired by Prostate Cancer UK, only 50% of centres
across UK offer mpMRI to the standard reported within the
PROMIS [9].This is because ﬁrstly, mpMRI scan quality is
variable across centres (of note, ~50% of scanners would need
replacement over the next 5 years [9]). Secondly, sufﬁciently
experienced radiologists are required to interpret these
complex scans. Lastly, there is a lack of detailed guidance for
clinicians in how to use mpMRI reports in making decisions
in clinic. Sub-optimal performance in any part of the pathway
reduces the potential beneﬁts of introducing mpMRI before
ﬁrst prostate biopsy, risking under-detection of clinically
signiﬁcant cancers if biopsies are avoided or over-calling of
scans, preventing men from beneﬁting from mpMRI’s triage
characteristics of avoiding a biopsy.
To address these challenges, a formal consensus process to
determine areas of agreement and disagreement within a
panel of UK experts in the ﬁeld of prostate cancer and/or
mpMRI was organised. The aims were to deﬁne criteria for
requesting, performing and reporting mpMRI scans,
addressing quality assurance (QA) of mpMRI, establishing the
requirements for mpMRI training, and guiding patient
management using mpMRI.
Materials and Methods
Design, Setting and Participants
A modiﬁed Research and Development Corporation and
University of California-Los Angeles (RAND-UCLA)
Appropriateness Method (RAM) was followed [10]. A
questionnaire containing 376 items was constructed by six
core panelists (H.A., C.A., A.B., A.K., C.M., S.P.) and
revisions were made following consultation with other
members. The items were identiﬁed based on differences in
practice across the UK and abroad without duplicating the
aims of previous consensus processes. The questionnaire was
divided into six sections: (i) Who can request prostate
mpMRI, (ii) Prostate mpMRI acquisition protocol updates,
(iii) Prostate mpMRI reporting, (iv) QA/quality control (QC)
of prostate mpMRI diagnostic process, (v) Management of
patients based on prostate mpMRI reports, and (vi) Training
in prostate mpMRI.
The diagnostic role of mpMRI in a pre-biopsy setting in men
at risk of prostate cancer was considered and the uses of
mpMRI for active surveillance of low-risk disease or post-
therapy follow-up were not addressed.
Panelists were selected due to their peer-reviewed publications
and expertise in prostate mpMRI and/or prostate cancer
management whilst ensuring a geographical spread. The
questionnaire was sent to 21 experts (eight radiologists, seven
urologists, two oncologists, three radiographers, and a
physicist). Eighteen participated in round 1 and ﬁfteen
attended the meeting. An independent non-scoring moderator
with signiﬁcant experience in leading consensus meetings
acted as chair.
Round 1: Individual Questionnaire Completion
Panelists were asked to rate their agreement with
questionnaire statements for which they considered they had
sufﬁcient expertise on a 9-point scale (ranging from 1
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‘strongly disagree’ to 9 ‘strongly agree’). If they lacked
expertise for a particular item, they scored ‘0’ to indicate that
they were non-scoring experts for that item.
Round 2: Face-to-Face Meeting Discussion
Fifteen attending panel members were shown the ﬁrst-round
score distribution for each questionnaire statement. After
each statement discussion, the panelists rescored the item.
Items scored by at least eight panel members were included
in the results. Nine consensus statements were added, 23
removed and 39 statements reworded for clarity. Eight items
responded to by less than eight panelists were excluded
reducing the number of consensus statements to 354.
Interpretation of the Results
We considered that there was ‘agreement’ with an individual
statement for a panel median score of ≥7 and ‘disagreement’
for a panel median score of ≤3. A score between 4 and 6
reﬂected ‘uncertainty’. Consideration for a particular item to
reach ‘consensus’ depended on the number of scoring panel
members as elaborated in the RAM [10].
Results
Pre-meeting consensus was reached in 127 of 376 items
(34%). During the meeting, consensus was reached in 208 of
354 items (59%). Table 1 shows the percentage of items
reaching consensus for each section of the questionnaire
before and after the face-to-face meeting. The Appendix S1
includes the detailed results for each questionnaire item.
Statements for which consensus was reached are summarised
below. Some statements for which consensus majority was
not reached are also discussed while mentioning that this was
‘agreement without consensus’.
Section I: Who Can Request Prostate mpMRI?
The panel agreed in consensus that mpMRI requests should
be made by urologists, uro-oncologists, and specialist urology
nurses. The latter would act mostly as a ﬁlter to determine
the appropriateness of all incoming requests. In the current
healthcare environment, any other clinical team may also be
able to request prostate mpMRI provided that there is prior
urological consultation, to ensure effective communication of
mpMRI results and continuity of care. There was consensus
that GPs should not directly request prostate mpMRI and
patients should not self-refer for prostate mpMRI.
It was also unanimously agreed that mpMRI should not be
offered to all men prior to clinical assessment and that an
elevated PSA should be assessed with other clinical factors
such as age, family history, DRE ﬁndings, PSA kinetics and
previous TRUS biopsy to determine referral for a prostate
mpMRI examination.
Section II: Updates on Prostate mpMRI Acquisition
Protocol
The panel focused on differences between previous UK
recommendations [11] and other international consensus
guidance such as Prostate Imaging and Reporting and Data
System (PI-RADS_v1 and _v2) [12,13]. The outcomes are
summarised in Table 2, with some elaborated on below.
Consensus was reached on orientating axial imaging to the
patient and not to the position of the prostate gland.
Although the latter is the orientation of choice for the
correspondence of MRI scans to prostatectomy specimens
particularly used in research, in the setting of men
undergoing surveillance with repeat scans to monitor any
Table 1 Number (%) of items reaching consensus in each section of the
questionnaire.
Section Pre-meeting Post-meeting
n/N (%)
consensus items
n/N (%)
consensus items
I. mpMRI requests 6/12 10/12
II. mpMRI acquisition
protocol updates
12/41 (29) 25/41 (61)
III. mpMRI clinical reporting 43/141 (30) 85/131 (65)
IV. QA/QC of mpMRI 44/100 (44) 47/89 (53)
V. Management of patients 12/56 (21) 24/54 (44)
VI. mpMRI training 10/26 (38) 17/27 (63)
Total 127/376 (34) 208/354 (59)
Table 2 Prostate mpMRI acquisition protocol updates.
Protocol updates
• The minimum and optimal ﬁeld strengths at which prostate mpMRI should be
conducted is 1.5 T and 3 T, respectively.
• Endorectal coils and rectal catheters for gas voiding do not need to be used
routinely.
• Anti-peristaltic agents should be incorporated in routine practice (unless contra-
indicated).
• Axial imaging should be orientated axial to the patient and not to the position of the
prostate gland.
• T2 sequences should be acquired in all three planes and should be obtained as three
separate acquisitions (axial, coronal and sagittal).
• Single 3D T2 imaging sequence was not adequate to replace the three separate 2D
acquisitions.
• T2 sequences with a large ﬁeld-of-view to cover abdominal nodes are not necessary.
• A maximum voxel size in-plane resolution of T2 sequences should be 0.7 mm or
better.
• The minimum high-b value for diffusion-weighted sequences should be b = 1 400 s/
mm2 at 1.5 T and b = 2 000 s/mm2 at 3 T.
• The maximum voxel size in-plane resolution of DWI should as far as possible
≤2 mm.
• Quantitative pharmacokinetic DCE-MRI modelling or curve shape parametric
evaluations are not necessary.
• DCE analysis should be performed with visual (qualitative) anatomical evaluation in
the early arterial enhancement images of the prostate.
• The temporal resolution of DCE-MRI sequences can be up to 15 s for a high spatial
resolution and anatomical interpretation of DCE images.
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interval change in lesion size, axial imaging to the patient was
considered helpful for improving consistency and
reproducibility of scans and lesion measurements albeit this
requires validation. Also direct intervention of radiologists
during the scan is reduced.
T2-Weighted Imaging (T2W)
The panel endorsed the previous statement [12] that this
sequence should be acquired in all three planes (the sagittal
plane being useful for pre-surgical planning and improved
visualisation of the bladder neck). In particular, T2W should
be obtained as three separate acquisitions (axial, coronal and
sagittal, two-dimensional [2D], fast-spin echo [FSE], multi-
slice) instead of single 3D acquisition until further research
on direct comparison of diagnostic quality and cancer
conspicuity of 2D vs 3D T2W for both peripheral zone (PZ)
and transition zone (TZ) are available [14,15]. The
maximum voxel size in-plane resolution of T2 sequences
should be ≤0.7 mm, in keeping with previous
recommendations [11,12]. The use of T2 sequences with a
large ﬁeld-of-view to cover abdominal nodes outside the
pelvis was questioned and was not considered as an
essential requirement, as MRI has a poor performance for
detection of nodal disease compared to functional imaging
techniques such as choline or prostate-speciﬁc membrane
antigen positron emission tomography (PET), especially
when there is clinical concern of nodal metastatic spread
[16,17].
Diffusion-Weighted Imaging (DWI) Sequences
The minimum high-b value for diffusion sequences should be
b = 1 400 s/mm2 at 1.5 T and b = 2 000 s/mm2 at 3 T
[11,12]. Although consensus was not reached, the majority
supported the preference for a separately acquired high b-
sequence over an extrapolated/calculated high b-value images.
Further evidence on the comparison between ‘extrapolated’ vs
‘separate’ high-b value image acquisitions for histology-
validated prostate cancer detection would be of value [18].
The maximum voxel size in-plane resolution of DWI should
as far as possible be kept at ≤2 mm as per previous UK
guidelines [11].
Dynamic Contrast-Enhanced Imaging (DCE)
The panel recognised that DCE-MRI is an essential
component of prostate mpMRI for detection, staging and
treatment planning [19,20]. DCE-MRI acts as a ‘safety net’ or
a ‘back-up’ mpMRI sequence especially when DWI images
are degraded, which is not uncommon in routine practice
(e.g. due to rectal gas). DCE-MRI analysis should be
performed visually, with anatomical evaluation in the early
arterial enhancement images of the prostate. Quantitative
pharmacokinetic DCE modelling or curve shape parametric
evaluation was deemed unnecessary. This means that the
temporal resolution can be up to 15 s between scans to allow
for a high spatial resolution and anatomical interpretation of
DCE-MRI images.
Section III: Standards for Prostate mpMRI Clinical
Reports
Table 3 summarises the outcomes of this section.
Who Can Report Prostate mpMRI?
Given the expertise required to report mpMRI, the panel
recommended that only uro-radiologists or radiologists with a
specialist interest in prostate cancer imaging should produce
prostate mpMRI reports. They should report at least 100
mpMRI examinations per year with the requirement of an
active participation in multi-disciplinary team (MDT)
meetings of at least twice a month. Other specialists (general
radiologists, MR radiographers, urologists or uro-oncologists)
should only be able to review/demonstrate prostate mpMRI
ﬁndings within the scope of their practice (e.g. a urologist
would review an MRI prior to performing a targeted biopsy,
but the images would already have been formally reported by
a radiologist with prostate MRI expertise).
Table 3 Consensus recommendations on clinical mpMRI reports.
Recommendations on clinical mpMRI reports
• The image quality of the mpMRI be reported.
• mpMRI should be scored to rule out Gleason score 7 (including 3 + prominent 4),
and/or volume ≥0.5 mL, and/or extraprostatic extension/seminal vesicle invasion.
• The mpMRI scoring system recommended is the ‘Likert-assessment’ system (both for
lesion-scoring and whole-gland scoring).
• Equivocal prostate mpMRI (Likert-impression 3) should be double-read if avoiding
biopsy is under consideration.
• Discordant mpMRI scores with biopsy results should be retrospectively double-read.
• The following should be scored on a 1–5 scale for likelihood of involvement: Extraprostatic extension.
 Seminal vesicle involvement.
 Bladder neck involvement.
 Neurovascular bundle involvement.
 External sphincter involvement.
 Rectal wall involvement.
 Bladder wall involvement.
 Peripheral zone (PZ) and Transition zone (TZ) tumour should be measured
from any sequence on which it is best seen.
• The following quantitative metrics should be included within an mpMRI report:
 Prostate gland volume and tumour size should be measured on T2-weighted
imaging using 3-diameters 9 0.52 (prolate ellipse formula).
 To ensure consistency, tumour should be measured as 3-diameters or volume
estimation by the product of 3 diameters 9 0.52.
 For software-targeted biopsy purposes, tumour should be contoured on the
sequence required by targeted biopsy fusion software.
 For targeted biopsy purposes, in a lesion >1 cm, the most suspicious area/spot
for signiﬁcant tumour, (i.e. the ‘hot-spot’) should be additionally indicated (e.g.
by contouring, via arrow-heads, etc.).
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Signiﬁcant Cancer Deﬁnition Thresholds for mpMRI
Assessment
Acknowledging differences in opinions on the deﬁnitions of
signiﬁcant prostate cancer, there was consensus agreement to
align with the deﬁnitions of clinically signiﬁcant cancer as
described in PI-RADS_v2 [12]. Speciﬁcally, mpMRI should be
scored to rule out Gleason score ≥3+4 and/or volume
≥0.5 mL, and/or extraprostatic extension/seminal vesicle
invasion.
Prostate mpMRI Clinical Reports
There was consensus on the use of a 5-point Likert-
impression scale (based on the radiologist’s overall opinion
and experience without the use of a dominant MRI sequence)
to rate likelihood of clinically signiﬁcant disease in routine
reporting, as prospectively validated in the multi-centre
PROMIS study [8]. There was no consensus on the routine
use of the current ‘lesion-based only’ assessment PI-RADS_v2
scoring system or a concurrent use of PI-RADS_v2 and the
subjective Likert assessment in the UK. The panel
acknowledged the lack of direct comparisons between
subjective Likert assessment and PI-RADS_v2 scoring, as
comparisons to date involved Likert assessment and PI-
RADS_v1 [21,22]. The majority of the panel disagreed with
current PI-RADS_v2 reporting recommendations that lesion
size should be the only factor differentiating between a score
4 and 5 for the likelihood of tumour.
In addition to lesion-based assessment, the remainder of the
prostate should also be scored on a subjective 5-point Likert-
assessment scale, to assess the signiﬁcance of diffuse
‘background’ signal change within the gland, which may
potentially mask signiﬁcant tumour and prompt biopsy (as
illustrated in Fig. 1). Of note, whole-gland assessment is not
addressed in PI-RADS_v2. Prostate and tumour volume
should be reported (the sagittal plane to measure the antero-
posterior diameter and height of the gland, and the axial
plane for the width of gland were found to be more accurate
for gland volume estimation [23]; of note, the use of the
semi-ellipsoid formula for lesion volume estimation is
practical albeit not yet validated). It is not necessary to report
the apparent diffusion coefﬁcient (ADC) values of lesions
given the variability between scanners and centres [24,25].
When calculating PSA density, the panel recommended the
use of MR-based volumes over TRUS-based volume, for
greater accuracy [26].
For pictorial prostate diagrams, there was uncertainty over
routine use of either a minimum of 12-sector or extensive 36-
sector PIRADS_v2 diagram. However, the panel all
emphasised the beneﬁts of a clear identiﬁcation and an
effective description of all mpMRI visible lesion(s) – these
may be either: drawn on any sectored prostate template
diagram (either hand-drawn or computer-generated);
indicated/contoured on the sequence it is best visible in
picture archiving communications system; screenshot as key
images; saved as annotated images or indicated within the
narrative text by sequence and slice numbers.
Double-Reporting
While there is not a need to double-read all mpMRI, there
was agreement in consensus that equivocal prostate mpMRI
(Likert-impression 3) should be double-read, if avoiding
biopsy is under consideration. Also, discordant mpMRI scores
with biopsy results should be retrospectively re-read by a
different radiologist. Any uro-radiologist or radiologist with a
specialist interest in prostate mpMRI imaging meeting the
minimum requirements for independent reporting would be
deemed appropriate to double-read the scans.
Table 4 shows areas lacking consensus in the mpMRI
reporting section.
Section IV: QA/QC of Prostate mpMRI
Setting national quality standards to perform prostate mpMRI
was envisaged in this section, to parallel breast imaging,
where national quality standards are established to ensure
safe, reliable, and accurate imaging services at accredited
facilities.
However, as prostate cancer is not part of a national
screening programme, consensus was not achieved to deﬁne
stringent QA standards equivalent to breast imaging. This
would ultimately be within the remit and expertise of
accreditation bodies to be implemented in the future.
Nevertheless, some areas of the panel discussion covering
site-speciﬁc, scanner-speciﬁc, image-speciﬁc and radiologist-
speciﬁc QA aspects are highlighted below.
Although consensus was not reached, a majority of 67%
supported accreditation for sites performing prostate mpMRI,
which would be administered by a national body. An
accredited centre should be able to perform T2W, DWI and
DCE-MRI to the latest national guidelines and perform or
refer patients for biopsy, MDT-meeting discussions, and
treatment.
Moreover, it was agreed in consensus that every scanner
should undergo regular QA/QC procedures in order to
perform prostate mpMRI. This is already a routine scanner
QA requirement within NHS institutions. Detailed guidance
is available on the American College of Radiology (ACR)/
Association of American Physicists in Medicine (AAPM)
website [27].
For diagnostic image-quality assessment, qualitative and
quantitative assessments were discussed. Whilst the usefulness
© 2018 The Authors
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of quantitative image assessment was unclear, qualitative
assessment through visual image assessment by a radiologist
analysing the images (e.g. looking for artefacts to prompt
correction, assessing lesion conspicuity etc.) was recognised as
adequate to determine diagnostic acceptability.
For radiologists to maintain reporting performance over time,
the panel supported the use of combined self-performance
tests, external performance assessments, and institution-based
audits. The development of any online performance
assessment tools could feature non histology-validated MRI
cases to compare the radiologist’s performance to experts
and/or use histology-validated cases to evaluate the
radiologist’s sensitivity, speciﬁcity, false negatives/positives,
and accuracy for signiﬁcant cancer.
It was recognised that these performance characteristics
would not only reﬂect the expertise of the biopsy operator
but also the reporting radiologist. These assessments would
help identify under-performing radiologists to motivate self-
improvement, such as increasing the number of mpMRI
reporting backed by continuous feedback from experts or
peer-reviewers, second-reading by an experienced radiologist
for a set period, increasing mpMRI to pathology correlations,
e.g. over the next 6–12 months, before any re-evaluation.
Section V: Management of Patients After Prostate
mpMRI Results
Whilst not formally considering all clinical factors as items
for consensus voting, it was clear that pre-biopsy mpMRI
scoring should not be the only factor guiding decisions about
whether to biopsy. Other factors such as age, family history,
use of 5a-reductase inhibitors, comorbidities, total PSA, PSA
kinetics, PSA density, urine dipstick tests (to exclude
mpMRI
T2 b2000
Pictorial representation of the
prostate
Overall ‘Background’ Score
ADC DCE
A B
C
Fig. 1 (A) Shows the mpMRI of a 62-year-old man, with a PSA level of 4.4 ng/mL and a gland volume of 25 mL at the level of the mid-gland to apex
region. On T2W imaging, there is diffuse and patchy low T2 signal and a lower T2 signal at the right lateral gland, with an equivocal high signal focus
on diffusion high b value at 9 o’clock and corresponding equivocal low ADC signal with bilateral enhancement on DCE. The focal lesion (represented
by number 1 in 1. (B) was reported with a Likert-assessment of 3/5. Besides, the remainder of the gland was also assessed with the whole prostate
divided into quarters for Likert assessment (C). Each quarter was reported as a ‘Likert-assessment’ 3/5. The background changes scored 3 are
represented by the shaded area in B. Upon transperineal template mapping biopsy, the prostate was found to harbour adenocarcinoma Gleason 3+4,
(40% biopsy core involvement) at the right posterior apex, focal high-grade prostatic intraepithelial neoplasia at the left posterior apex and Gleason
3+3, at eight different sites within the prostate (10–40% biopsy core involvement).
Table 4 Shows areas lacking consensus in clinical mpMRI reporting.
Areas lacking consensus in clinical mpMRI reporting
• PI-RADS_v2 scoring system may be used during training/gaining experience
before switching to the use of subjective Likert-impression once experienced.
• The narrative report should refer to the sectors as named in the PI-RADS_v2
pictorial report used: e.g. sectors named PZpl (postero-lateral PZ), PZpm
(posteromedial PZ), TZp (posterior TZ), TZa (anterior TZ), etc.).
• In the pictorial report, the prostate diagram should be represented in all three
planes.
• mpMRI suspicious lesions contouring should be performed only when targeted
biopsy or focal treatment is planned.
• Tumour volume should be calculated by summation of contoured areas on each
slice of the tumour/software rendering.
• Transition zone (TZ) tumour should be measured from T2 only (as in PI-
RADS_v2).
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infection), prior biopsy results, and patient preference, might
be considered in conjunction.
When pre-biopsy mpMRI is scored 1–2 (not suspicious for
clinically signiﬁcant cancer) and the PSA density is below an
agreed threshold, it was agreed in consensus that the patient
can be discharged to the GP with PSA follow-up, i.e. no
immediate biopsy is required. However, where PSA density is
above the agreed threshold, then biopsy should be discussed
with the patient as part of a shared decision-making process
discussing risks of disease being present (~0–24% of negative
mpMRI harbour signiﬁcant cancer depending on the
deﬁnition used [2,8,28–34] and the risks related to the biopsy
procedure. The recommended biopsy technique for men who
on clinical grounds, are advised or choose to have a biopsy
despite a unsuspicious mpMRI is by any transperineal
systematic biopsy (10/12, 83% panelists) due to no visible MR
target; systematic TRUS biopsy would only increase the
detection rate by 1–2% [31,32] and was not deemed
worthwhile in the presence of unsuspicious mpMRI.
For equivocal mpMRI impressions (Likert-assessment 3), a
biopsy is recommended when the PSA density is above an
agreed threshold (unanimous consensus). There was
agreement but not in consensus that young patients (seven of
12 panelists) and with positive family history (eight of 12
panelists) could also undergo biopsy if the mpMRI was
scored 3. It was agreed but not in consensus that biopsy
options in equivocal mpMRI should include MR-guided
biopsy (visually estimated, image fusion or in-bore; eight of
12 panelists), transperineal systematic biopsy (seven of 12
panelists) or combined targeted and systematic sampling
(seven of 12 panelists) of the gland. Emerging evidence shows
no statistical difference between the use of combined targeted
and systematic biopsy vs each biopsy technique alone for
signiﬁcant cancer detection in equivocal lesions [35].
Immediate biopsy is recommended for suspicious pre-biopsy
mpMRI (Likert-assessment 4–5); Suspicious mpMRI followed
by negative targeted biopsy should be discussed as part of an
MDT meeting for collective management decision, where the
possibility of a missed targeted biopsy, or of a false-positive
mpMRI report would both be considered. Table 5
summarises this section’s discussion.
Section VI: Training in Prostate mpMRI Reporting
It was unanimously agreed that prostate mpMRI reporting
cannot be self-taught. Before commencing independent
mpMRI reporting, radiologists should undertake a
combination of core theoretical prostate mpMRI course,
hands-on practice at workstations with supervised reporting,
and should also participate in MDT meetings or attend
MDT-type workshops where patient-based clinical scenarios
are discussed. Training should be dispensed and certiﬁed by
national bodies such as the Royal College of Radiologists.
Table 6 highlights the areas of agreement of the panel within
this section.
Figure 2 summarises key recommendations from this process.
Discussion
The present paper reports formal UK recommendations from
a RAM consensus process to guide the practice of pre-biopsy
prostate mpMRI in expert and non-expert centres.
Recommendations have been made to ensure consistently
high-quality mpMRI scans and improve standards in
reporting to offer better guidance in management decisions.
Clinical Implications
There are a number of key statements that we believe will be
of signiﬁcant impact in the UK prostate cancer diagnostic
pathway.
First, we have laid down the minimum conditions for a
prostate mpMRI. This includes the added value of DCE-MRI,
which has been lately questioned [36–41]. A recent UK audit
revealed that 24% of NHS centres do not conduct prostate
MRI with DCE [9]; it was found that the main reason for
non-compliance with the UK and PI-RADS guidelines [11,12]
was due to capacity problems. However, the panel still
recommends the use of DCE as integral to prostate MRI, i.e.
which evolves from bi-parametric (T2W and DWI) to
mpMRI, with the addition of DCE-MRI. The beneﬁts of
DCE-MRI include the fact that it acts as a back-up to
overcome technical failures from DWI and artefacts (such as
susceptibility artefact from rectal gas and distortion from hip
replacement), which hinder diagnostic accuracy [19,42–45].
Besides, DCE-MRI is helpful for the less experienced
radiologists [46] and also beneﬁcial in differentiating the
anterior ﬁbromuscular stroma from anterior tumours [47].
DCE-MRI can also act as a ‘safety’ sequence in patients
where diffusion images are signiﬁcantly distorted by
susceptibility artefact from air within the rectum or total hip
Table 5 Recommendations for incorporation of mpMRI scores in patient’s
management.
Recommendations for incorporation of mpMRI scores in patient’s
management
mpMRI scores 1–2
• No immediate biopsy is recommended.
• Biopsy can be considered as part of a shared decision process with the patient if
• PSA density is elevated or clinical concerns persist.
mpMRI score 3
• Immediate biopsy if PSA density is elevated.
mpMRI scores 4–5
• Immediate biopsy.
mpMRI scores 4–5 and targeted biopsy is negative
• Discuss in MDT meeting.
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replacements. Furthermore, DCE also improves the
conﬁdence regarding identiﬁed lesions particularly for those
of an indeterminate nature [19,48,49].
Second, we also questioned the widespread use of PI-
RADS_v2 scoring system and recommended the use of a
subjective 5-point Likert-assessment of mpMRI scans in the
UK pending higher-level validation and further evolution of
the PI-RADS scoring system (noting that PI-RADS_v3 is
currently under development). Although PI-RADS_v2
promotes an objective lesion-based scoring approach [12], it
does not include routine assessment of the whole prostate,
e.g. the signiﬁcance of diffuse ‘background’ signal change
within the whole gland is often not addressed [50]. Even
though the dominance of a sequence in PZ/TZ lesion
evaluation was acknowledged, tumours exhibiting strong
cancer suspicion on the non-dominant sequence (e.g. T2 in
the PZ or ADC in the TZ) could be missed with PI-
RADS_v2. Also, the latter does not ﬁt in other areas, i.e.
central zone, anterior stroma and zonal interface where zonal
origin unclear. These are areas where a ‘Likert-impression’
score can be more useful. Nevertheless, radiologists can use
the descriptive scoring characteristics as elaborated in PI-
RADS_v2 to guide their opinions and supplement them with
their own experience, as well as features outside of PI-
RADS_v2 criteria to form an overall subjective Likert-
impression. The panel also acknowledged that mpMRI
descriptive features in the PIRADS_v2 guidelines are
particularly useful for the less experienced and for research.
Furthermore, they discussed the need for a histologically-
validated pictorial guide to illustrate subjective Likert-
impressions and this could be delivered through datasets
acquired during clinical trials.
Third, in order to maintain quality mpMRI reporting and
guarantee accurate and safe prostate mpMRI reports,
minimum standards for reporting radiologists were tackled.
Although the effect of dedicated training on the accuracy
of prostate cancer localisation on mpMRI, the effect of
continual feedback on reporting conﬁdence and a ‘learning
curve’ effect have been documented, the establishment of a
threshold number of prostate mpMRI required during
training, to reach independent reporting and to maintain
expertise are lacking [51–54]. While some may not agree
with the concept of quantitative metrics to gauge quality or
experience, the majority of the panel agreed that an
independent radiologist should report >100 prostate
mpMRI scans per year with regular attendance to MDT
meetings of at least twice a month. Also, prior to
independent reporting, supervised reporting of at least 100
mpMRI studies were deemed appropriate. Moreover, centres
carrying out at least 250 cases per year were regarded as
best suited to dispense training. These numbers are under
the proviso that the scans also meet the minimum quality
requirement as per the latest protocol guidelines.
Furthermore, it was stressed that general radiologists are
not to report prostate mpMRI unless they have a specialist
interest in prostate mpMRI, and like uro-radiolgists are
prepared to meet the necessary minimum requirements in
terms of training and experience, prior to autonomous
reporting.
This expert group initiated the discussion regarding prostate
mpMRI-speciﬁc QA, but it was recognised that more
specialist technical groups with speciﬁc QA expertise are
required to set-up relevant QA requirements across the whole
prostate cancer pathway including QA procedures for
pathology, surgery, and data collection. QA requirements for
breast cancer diagnosis pathway [55] could be used as an
exemplar approach.
Last, we considered who should be biopsied based on
mpMRI reports. There was consensus that mpMRI report
should be used to determine whether a man should be
biopsied, capitalising on the high sensitivity and high
negative-predictive values for mpMRI in excluding clinically
signiﬁcant prostate cancer and between one-quarter and
one-third of men would be given the opportunity to avoid
an immediate biopsy. Growing literature on the combined
use of PSA density with mpMRI as an additional factor to
reduce the false negatives of mpMRI [50,56–61] was
endorsed by the panel to better select patients for biopsy
after non-suspicious and equivocal mpMRI [35,57,62].
Whilst various PSA density thresholds have been previously
suggested [63–65], the threshold of 0.15 ng/mL/mL is
proving to be useful in the diagnostic setting [57–59,66],
although individual centres may choose to be more
conservative in using lower PSA density threshold (e.g.
0.12 ng/mL/mL) alongside other risk factors in deciding
which men can avoid a biopsy until more robust evidence is
available.
Table 6 Summarises the recommendations in the training section.
Agreement in consensus
• There should be a competency examination in prostate mpMRI prior to starting
independent reporting.
• Attendance on a training course should be made mandatory prior to starting
independent reporting.
• There should be evidence of self-directed learning.
• Prostate mpMRI training course for non-reporters should differ from the reporters’
course and adapted to their specialty ﬁeld.
• There should be a national accreditation for prostate mpMRI reporting.
• Certiﬁed, standardised training for prostate mpMRI should be provided by a national
body.
• Prior to commencing independent mpMRI reporting, reporters should attend a
combination of:
 A core theoretical mpMRI course.
 Hands-on practice at workstations.
 Supervised reporting.
 MDT-type workshops aimed at discussing patient-based clinical scenarios.
• Hands-on training may be given by centres carrying out a minimum number of
≥250 cases/year.
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Research Implications
Some areas did not reach consensus, due to conﬂicting results
or lack of data in the literature to guide discussions. Areas of
further research include: lesion detection/conspicuity
comparisons from dedicated vs extrapolated/computed long
b-values at 3 T and 1.5 T without endorectal coils;
quantitative image quality assessments; speciﬁc MR-prostate
phantom development; threshold number of mpMRI studies
required during and after prostate mpMRI training and to
reach autonomous reporting; long-term clinical risk of cancer
and outcomes of high-grade prostatic intraepithelial neoplasia
(HGPIN), atypical small acinar proliferation (ASAP), atrophy
or inﬂammation upon diagnosis for mpMRI directed
management options [67,68]; and combining mpMRI with
molecular/genomic biomarkers, risk-calculators (other than
TRUS-biopsy validated ones) across the prostate cancer
pathway for diagnosis.
Methodological Limitations
Expert group discussions are prone to biases, but latest
available evidence was used and an independent chair
ensured balanced debates. Even if one or two panelists
dominated the discussion, they had only one vote. Besides,
some members of the panel scored the items before the
meeting but were not present in the face-to-face meeting.
Whilst a GP representative on our panel would have been
Clinical
Suspicion of 
prostate cancer
Quality Assurance
of
prostate mpMRI
Every scanner should
undergo regular quality
assurance/quality control
procedures in order to 
perform prostate mpMRI
For diagnostic acceptability
of studies, qualitative 
assessment (artefact
assessment) by a
radiologist is recognised as 
adequate
Self-performance tests,
external performance
assessments and
institution-based audits are
encouraged
Prostate mpMRI cannot
be self-taught
- Immediate biopsy is
recommended in
suspicious mpMRI
(scores 4-5)
There is not a need to
double-read all prostate
mpMRI studies
- 3D T2 acquisition
should not replace three
separately T2W acquired
orientations
- Separately acquired
DWI high b-value is
preferred to extrapolated
high b-values
- A 5-point Likert
assessment backed
by experience & overall
opinion is recommended to
rate likelihood for presense
of cancer
- Lesions & the rest
(background changes) of
the prostate should be
assessed for presence of
cancer
To maintain expertise
radiologists should
-report ≥100 studies/year
and
- attend at least biomonthly
MDT meetings
For patients with
equivocal mpMRI (score
3) AND an elevated PSA
density, an immediate
biopsy is recommended
- Biopsy decisions should
not be made based only 
on mpMRI assessment
- Uro-radiologists/
radiologists with specialist
interest in prostate should
report mpMRI
- DCE-MRI is an 
essential companent of 
prostate mpMRI
mpMRI requests should
be made only after
clinical assessment by:
- urologists
- uro-oncologists
- specialist urology
nurses (filtering
appropriateness of
requests)
- DCE analysis should be
performed qualitatively in
early-enhancement
phase
- MpMRI should rule out
Gleason≥7 cancer and/or
tumor volume≥0.5cc
and/or EPE/SV invasion
Prior to independant
reporting, a combination of 
- core theorectical mpMRI
courses,
- hands-on practice at
workstations with
supervised reporting,
- active MDT meetings
participation is required
- Patients with non-
suspicious mpMRI (scores
1-2) AND a low PSA
density do not require
immediate biopsy
- Temporal resolution of
DCE-MRI can be up to
15s to allow for
anatomical interpretation
- Axial imaging should be
orientated axial to the
patient and not to
prostate position
Double-reading of 
equivocal mpMRI or
discordant mpMRI with
biopsy results are
recommended
- Management of 
suspicious pre-biopsy
mpMRI with negative
targeted biopsy should be
collectively discussed in
MDT meetings
- General Practitioners
should not request an
mpMRI on their own
Other clinical teams can
request prostate mpMRI
provided there is prior
consultation with the
urological team
- Patients cannot be self-
referred for mpMRI
Request for
Prostate
Multi-parametric
MRI
Prostate
Multi-parametric
MRI Acquisition
Prostate
Multi-parametric
MRI Reporting
Prostate
Multi-parametric
MRI: Training &
Maintaining
Expertise
Patient management
based on mpMRI
suspicion levels
for cancer
Fig. 2 Summarises the key recommendations across the early prostate cancer diagnosis pathway to deliver consistently high-quality mpMRI studies.
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beneﬁcial to address the initial questions involving GPs, the
contribution to the remainder of the document would be
limited. Finally, this process does not aim to reach consensus
in areas of disagreement or minimise uncertainties in clinical
areas but it has helped to identify areas warranting additional
research.
Conclusions
The promise of mpMRI is reﬂected by the rapid uptake of
this investigation into clinical practice and the growing
demand to offer this test across the UK. Our consensus
statements demonstrate a set of criteria that are required for
the reliable dissemination of prostate mpMRI as a diagnostic
test prior to biopsy in men at risk. It is of utmost importance
that quality should be maintained across the whole prostate
pathway in all healthcare settings for prostate mpMRI to be
used as a tool to rule in and rule out clinically signiﬁcant
prostate cancer.
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